Since receiving its cultivation license, the growing space at Beleave Inc.’s (BE: CNX) facility near Hamilton,
Ont., has been prepared, and rooted starting material has been planted. The
company anticipates it will commence its first flowering cycle in the next week,
with this cycle, in its entirety, scheduled to last approximately eight weeks.

The
company will use its multiroom indoor perpetual growing methodology and has
anticipated a harvest to take place approximately every seven weeks after the
completion of the first. The first crop will consist of three batches of strain
offerings with varying tetrahydrocannabinol/cannabidiol concentrations. In
the coming weeks, two additional strain offerings will be introduced to
complete an agreed upon spectrum.

The
Beleave team is also working diligently, with the support of its expert
consultants and advisors, to satisfy all remaining requirements for a sales
licence from Health Canada.

About Beleave Inc.

Beleave
is a biotech company. Its wholly owned subsidiary First Access Medical Inc. is
a licensed producer pursuant to the ACMPR (access to cannabis for medical
purposes regulations). Beleave’s purpose-built facility is in Hamilton, Ont.

In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.